Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immuneering Corp IMRX

Healthcare Biotechnology
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve... see more

Recent & Breaking News (NDAQ:IMRX)

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 8 days ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

GlobeNewswire October 15, 2024

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

GlobeNewswire September 12, 2024

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 29, 2024

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 6, 2024

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

GlobeNewswire July 31, 2024

Immuneering to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 7, 2024

Immuneering Recognizes Melanoma Awareness Month

GlobeNewswire May 6, 2024

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

GlobeNewswire April 9, 2024

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

GlobeNewswire March 27, 2024

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

GlobeNewswire March 14, 2024

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

GlobeNewswire March 12, 2024

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

GlobeNewswire March 11, 2024

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

GlobeNewswire March 5, 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

GlobeNewswire March 4, 2024

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire March 1, 2024

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

GlobeNewswire February 20, 2024

Immuneering Announces Participation in February Investor Conferences

GlobeNewswire February 1, 2024